Celgene, Agios Ready For Enasidenib Launch After Early Approval

Idhifa is the first treatment for AML patients with IDH2 mutations. The drug will be co-commercialized by Celgene and Agios under their 2010 collaboration and is the latter's first regulatory approval.

Digital illustration of Cancer cell in colour background

Celgene Corp. and partner Agios Pharmaceuticals Inc. are ready to quickly capitalize on FDA approval of Idhifa (enasidenib), which came nearly a month earlier than its Aug. 30 priority review user fee date, for a subset of relapsed or refractory acute myeloid leukemia patients, giving Agios its first approved drug and Celgene the initial fruits of a collaboration inked in 2010.

Idhifa, an oral, targeted inhibitor of the isocitrate dehydrogenase-2 (IDH2) enzyme, was approved Aug.1 to treat adult AML patients with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

More from Scrip

China’s Biotechs Were The Small-Cap Rising Stars In H1 2025

 

The list of small-cap companies with the fastest-rising share prices so far this year is dominated by Chinese companies, underscoring their growing contribution to the global biopharma ecosystem.

In Brief: Soleno To Raise $200m To Boost Vykat XR Launch

 
• By 

Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.